UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number: 001-36515
Materialise NV
Technologielaan 15
3001 Leuven
Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
This Form 6-K is incorporated by reference into the registrant’s Registration Statement on Form F-3 (File No. 333-213649).
Third Quarter 2026 Results
Except as otherwise required by the context, references to “Materialise,” “Company,” “we,” “us,” and “our” are to Materialise NV and its subsidiaries.
Third Quarter 2026 Financial Results
Total revenue for the third quarter of 2026 increased by 2.1% to 67,670 kEUR from 66,259 kEUR for the third quarter of 2025.
Revenue from our Materialise Medical segment increased 9.7% to 36,542 kEUR for the third quarter of 2026 compared to 33,296 kEUR for the same period in 2025.
Revenue from our Materialise Software segment was 9,864 kEUR for the third quarter of 2026 compared to 10,286 kEUR for the same quarter last year.
Revenue from our Materialise Manufacturing segment was 21,266 kEUR for the third quarter of 2026 compared to 22,677 kEUR for the third quarter of 2025.
Gross profit increased 3.7% to 39,035 kEUR for the third quarter of 2026 compared to 37,651 kEUR for the same period last year. Gross profit as a percentage of revenue was 57.7% compared to 56.8% for the third quarter of 2025.
Research and development (“R&D”), sales and marketing (“S&M”), and general and administrative (“G&A”) expenses increased, in the aggregate, by 7.8% to 38,830 kEUR for the third quarter of 2026 from 36,019 kEUR for the third quarter of 2025 mainly driven by 11.9% higher R&D spend.
Net other operating income was 1,137 kEUR compared to 890 kEUR for the third quarter of 2025.
Net operating income in the third quarter of 2026 includes non-recurring charges of 184 kEUR from the impairment of inventory related to the transfer of the Eyewear assets.
Operating profit was 1,343 kEUR for the third quarter of 2026, compared to 2,522 kEUR for the third quarter of 2025.
Net financial result was 160 kEUR for the third quarter of 2026, compared to (121) kEUR for the third quarter of 2025.
The third quarter of 2026 contained net tax expenses of (120) kEUR, compared to net tax expenses of (553) kEUR in the third quarter of 2025.
As a result of the above, net profit for the third quarter of 2026 was 1,383 kEUR, compared to 1,848 kEUR for the same period in 2025.
Cash flow from operating activities for the third quarter of 2026 amounted to 9,666 kEUR compared to 10,359 kEUR for the same period in 2025. Total cash used for capital expenditures for the third quarter of 2026 amounted to 2,146 kEUR and free cash flow after operating and investing activities was 11,419 kEUR.At September 30, 2026, cash and cash equivalents increased to 153,529 kEUR from 133,918 kEUR at December 31, 2025.
Gross debt increased to 71,056 kEUR from 63,113 kEUR at December 31, 2025. As a result, our net cash position increased by 11,668 kEUR to 82,473 kEUR compared to 70,805 kEUR as of December 31, 2025. At the end of the third quarter of 2026 Materialise had repurchased 1,426,784 own shares for a total amount (excluding transaction cost) of 7,482 kEUR (8,698 kUSD) under its previously announced share buy-back program.
Net shareholders' equity at September 30, 2026 increased to 255,809 kEUR compared to 255,482 kEUR at December 31, 2025.
Adjusted EBIT amounted to 2,485 kEUR for the third quarter of 2026 compared to 2,918 kEUR for the 2025 period. The Adjusted EBIT margin (Adjusted EBIT divided by total revenue) for the third quarter of 2026 was 3.7%, compared to 4.4% for the third quarter of 2025. Adjusted EBITDA for the third quarter of 2026 amounted to 8,046 kEUR compared to 8,428 kEUR for the 2025 period.
Adjusted EBITDA from our Materialise Medical segment amounted to 10,015 kEUR for the third quarter of 2026 compared to 10,199 kEUR for the corresponding period in 2025, while the Adjusted EBITDA margin for the segment (segment Adjusted EBITDA divided by segment revenue) was 27.4% compared to 30.6% for the third quarter of 2025.
Adjusted EBITDA from our Materialise Software segment amounted to 1,463 kEUR for the third quarter of 2026 compared to 1,801 kEUR for the corresponding period in 2025, while the Adjusted EBITDA margin for the segment was 14.8% compared to 17.5% for the prior-year period.
Adjusted EBITDA from our Materialise Manufacturing segment improved to (257) kEUR for the third quarter of 2026 compared to (845) kEUR for the same period in 2025, while the Adjusted EBITDA margin for the segment was (1.2)% compared to (3.7)% for the third quarter of 2025.
Non-IFRS Measures
Materialise uses EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA as supplemental financial measures of its financial performance, including for purposes of monitoring compliance with financial covenants, supporting discussions with financing institutions, and meeting reporting requirements to our banks. EBIT is calculated as net profit plus income taxes, financial expenses (less financial income) and shares of profit or loss in a joint venture. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of profit or loss in a joint venture and depreciation and amortization. Adjusted EBIT and Adjusted EBITDA are determined by adding to EBIT and EBITDA, respectively (i) share-based compensation expenses, (ii) acquisition expenses related to business combinations or divestiture-related expenses, (iii) impairments and revaluation of fair value due to business combinations and (iv) costs incurred in relation to corporate initiatives, restructurings or reorganizations that are of a non-recurring nature. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of financing decisions and, in the case of EBITDA and Adjusted EBITDA, long term investment, rather than the performance of the company’s day-to-day operations. The company also uses segment Adjusted EBITDA and segment Adjusted EBITDA margin to evaluate the performance of its three business segments. As compared to net profit, these measures are limited in that they do not reflect the cash requirements necessary to service interest or principal payments on the company’s indebtedness and, in the case of EBITDA and Adjusted EBITDA, these measures are further limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company’s business, or the changes associated with impairments. Management evaluates such items through other financial measures such as financial expenses, capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The company’s calculation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company’s presentation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.
Exchange Rate
This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.1355, the reference rate of the European Central Bank on September 30, 2026.
About Materialise
Materialise NV incorporates more than three decades of 3D printing experience into a range of software solutions and 3D printing services that empower sustainable 3D printing applications. Our open, secure, and innovative end-to-end solutions enable flexible industrial manufacturing and mass personalization in various industries — including healthcare, automotive, aerospace, art and design, wearables, and consumer goods. Headquartered in Belgium and with branches worldwide, Materialise NV combines the largest group of software developers in the industry with one of the world's largest and most complete 3D printing facilities. For additional information, please visit: www.materialise.com.
Consolidated income statements (Unaudited)
| for the three months ended September 30, | for the nine months ended September 30, | ||||||||||||||
| In '000 | 2026 | 2026 | 2025 | 2026 | 2025 | ||||||||||
| U.S.$ | € | € | € | € | |||||||||||
| Revenue | 76,840 | 67,670 | 66,259 | 204,020 | 197,469 | ||||||||||
| Cost of Sales | (32,515 | ) | (28,635 | ) | (28,608 | ) | (87,314 | ) | (85,298 | ) | |||||
| Gross Profit | 44,324 | 39,035 | 37,651 | 116,705 | 112,171 | ||||||||||
| Gross profit as % of revenue | 57.7 | % | 57.7 | % | 56.8 | % | 57.2 | % | 56.8 | % | |||||
| Research and development expenses | (14,540 | ) | (12,805 | ) | (11,439 | ) | (37,008 | ) | (33,973 | ) | |||||
| Sales and marketing expenses | (17,670 | ) | (15,561 | ) | (14,847 | ) | (46,206 | ) | (45,386 | ) | |||||
| General and administrative expenses | (11,882 | ) | (10,464 | ) | (9,733 | ) | (30,087 | ) | (29,506 | ) | |||||
| Net other operating income/(expense) | 1,292 | 1,137 | 890 | 2,813 | 2,519 | ||||||||||
| Operating profit (loss) | 1,524 | 1,343 | 2,522 | 6,218 | 5,825 | ||||||||||
| Financial expenses | (1,281 | ) | (1,128 | ) | (582 | ) | (2,699 | ) | (7,393 | ) | |||||
| Financial income | 1,463 | 1,289 | 460 | 3,494 | 3,345 | ||||||||||
| Profit (loss) before taxes | 1,706 | 1,503 | 2,401 | 7,012 | 1,777 | ||||||||||
| Income tax benefit/(expense) | (136 | ) | (120 | ) | (553 | ) | (478 | ) | (266 | ) | |||||
| Net profit (loss) for the period | 1,570 | 1,383 | 1,848 | 6,535 | 1,510 | ||||||||||
| Net profit (loss) attributable to: | |||||||||||||||
| The owners of the parent | 1,562 | 1,376 | 1,848 | 6,527 | 1,512 | ||||||||||
| Non-controlling interest | 8 | 7 | - | 7 | (2 | ) | |||||||||
| Earnings per share attributable to owners of the parent | |||||||||||||||
| Basic | 0.03 | 0.02 | 0.03 | 0.11 | 0.03 | ||||||||||
| Diluted | 0.03 | 0.02 | 0.03 | 0.11 | 0.03 | ||||||||||
| Weighted average basic shares outstanding | 57,839 | 57,839 | 59,067 | 58,334 | 59,067 | ||||||||||
| Weighted average diluted shares outstanding | 58,061 | 58,061 | 59,067 | 58,397 | 59,071 | ||||||||||
Consolidated statements of comprehensive income (Unaudited)
| for the three months ended September 30, | for the nine months ended September 30, | ||||||||||
| In 000€ | 2026 | 2026 | 2025 | 2026 | 2025 | ||||||
| U.S.$ | € | € | € | € | |||||||
| Net profit (loss) for the period | 1,570 | 1,383 | 1,848 | 6,535 | 1,510 | ||||||
| Other comprehensive income/(loss) | |||||||||||
| Items that are or may be reclassified subsequently to profit or loss | |||||||||||
| Exchange difference on translation of foreign operations | 16 | 14 | 38 | 270 | 1,167 | ||||||
| Exchange differences resulting from net investment in foreign operations | 69 | 61 | - | 598 | - | ||||||
| Other comprehensive income/(loss), net of taxes | 85 | 75 | 38 | 868 | 1,167 | ||||||
| Total comprehensive income/(loss), net of taxes | 1,656 | 1,458 | 1,885 | 7,403 | 2,677 | ||||||
| Total comprehensive income/(loss) attributable to: | |||||||||||
| The owners of the parent | 1,649 | 1,452 | 1,886 | 7,401 | 2,670 | ||||||
| Non-controlling interests | 7 | 6 | (0 | ) | 1 | 7 | |||||
Consolidated statement of financial position (Unaudited)
| As of September 30, | As of December 31, | |||||||
| In 000€ | 2026 | 2025 | ||||||
| Assets | ||||||||
| Non-current assets | ||||||||
| Goodwill | 43,230 | 43,161 | ||||||
| Intangible assets | 22,217 | 25,639 | ||||||
| Property, plant & equipment | 110,301 | 112,854 | ||||||
| Right-of-Use assets | 5,688 | 5,429 | ||||||
| Deferred tax assets | 4,122 | 3,971 | ||||||
| Investments in convertible loans | 410 | - | ||||||
| Investments in non-listed equity instruments | 8 | - | ||||||
| Other non-current assets | 10,623 | 5,983 | ||||||
| Total non-current assets | 196,599 | 197,038 | ||||||
| Current assets | ||||||||
| Inventories | 17,418 | 14,904 | ||||||
| Trade receivables | 48,783 | 54,938 | ||||||
| Other current assets | 13,247 | 15,533 | ||||||
| Cash and cash equivalents | 153,529 | 133,918 | ||||||
| Assets held for sale | - | 4,314 | ||||||
| Total current assets | 232,977 | 223,607 | ||||||
| Total assets | 429,576 | 420,646 | ||||||
| As of September 30, | As of December 31, | |||||||
| In 000€ | 2026 | 2025 | ||||||
| Equity and liabilities | ||||||||
| Equity | ||||||||
| Share capital | 4,487 | 4,487 | ||||||
| Share premium | 203,895 | 203,895 | ||||||
| Treasury shares | (7,507 | ) | - | |||||
| Retained earnings and other reserves | 55,013 | 47,180 | ||||||
| Equity attributable to the owners of the parent | 255,888 | 255,562 | ||||||
| Non-controlling interest | (79 | ) | (80 | ) | ||||
| Total equity | 255,809 | 255,482 | ||||||
| Non-current liabilities | ||||||||
| Loans & borrowings | 59,215 | 49,726 | ||||||
| Lease liabilities | 3,293 | 3,063 | ||||||
| Deferred tax liabilities | 2,343 | 2,660 | ||||||
| Deferred income | 15,800 | 17,344 | ||||||
| Other non-current liabilities | 483 | 486 | ||||||
| Total non-current liabilities | 81,134 | 73,280 | ||||||
| Current liabilities | ||||||||
| Loans & borrowings | 5,947 | 7,759 | ||||||
| Lease liabilities | 2,601 | 2,565 | ||||||
| Trade payables | 20,927 | 20,125 | ||||||
| Tax payables | 464 | 748 | ||||||
| Deferred income | 43,359 | 43,523 | ||||||
| Other current liabilities | 19,334 | 16,362 | ||||||
| Liabilities held for sale | - | 802 | ||||||
| Total current liabilities | 92,633 | 91,884 | ||||||
| Total equity and liabilities | 429,576 | 420,646 | ||||||
Consolidated statement of cash flows (Unaudited)
| for the nine months ended September 30, | ||||||||
| In 000€ | 2026 | 2025 | ||||||
| Operating activities | ||||||||
| Net (loss) profit for the period | 6,535 | 1,510 | ||||||
| Non-cash and operational adjustments | ||||||||
| Depreciation of property plant & equipment | 12,475 | 11,317 | ||||||
| Amortization of intangible assets | 4,920 | 4,834 | ||||||
| Share-based payment expense | 475 | 191 | ||||||
| Loss (gain) on disposal of intangible assets and property, plant & equipment | (350 | ) | (24 | ) | ||||
| Government grants | (354 | ) | (209 | ) | ||||
| Movement in provisions | 466 | (273 | ) | |||||
| Movement reserve for bad debt and slow moving inventory | 451 | 194 | ||||||
| Financial income | (3,493 | ) | (3,339 | ) | ||||
| Financial expense | 2,705 | 7,385 | ||||||
| Impact of foreign currencies | (65 | ) | (137 | ) | ||||
| (Deferred) income taxes | 483 | 260 | ||||||
| Working capital adjustments and income tax (paid)/received | ||||||||
| Decrease (increase) in trade receivables and other receivables | 4,044 | 6,197 | ||||||
| Decrease (increase) in inventories and contracts in progress | (3,059 | ) | (1,604 | ) | ||||
| Increase in trade payables and other payables | (1,888 | ) | (6,875 | ) | ||||
| Income tax (paid)/received | (786 | ) | (1,358 | ) | ||||
| Interest received | 2,170 | 1,977 | ||||||
| Net cash flow from operating activities | 24,727 | 20,045 | ||||||
| for the nine months ended September 30, | ||||||||
| In 000€ | 2026 | 2025 | ||||||
| Investing activities | ||||||||
| Purchase of property, plant & equipment | (4,352 | ) | (10,372 | ) | ||||
| Purchase of intangible assets | (1,238 | ) | (1,477 | ) | ||||
| Proceeds from the sale of property, plant & equipment & intangible assets | 358 | 231 | ||||||
| Cash transferred out upon divestment | (488 | ) | - | |||||
| Investments in associates and joint ventures | (8 | ) | - | |||||
| (Convertible) loan to third party | (459 | ) | - | |||||
| Capital government grants received | 4,249 | 2,678 | ||||||
| Net cash flow used in investing activities | (1,938 | ) | (8,940 | ) | ||||
| Financing activities | ||||||||
| Proceeds from loans & borrowings | 15,000 | 35,000 | ||||||
| Repayment of loans & borrowings | (7,314 | ) | (10,461 | ) | ||||
| Repayment of leases | (2,668 | ) | (2,257 | ) | ||||
| Interest paid | (1,568 | ) | (1,209 | ) | ||||
| Other financial income (expense), net | (37 | ) | (1,515 | ) | ||||
| Repurchase of treasury shares | (7,276 | ) | - | |||||
| Net cash flow from (used in) financing activities | (3,862 | ) | 19,558 | |||||
| Net increase/(decrease) of cash & cash equivalents | 18,926 | 30,663 | ||||||
| Cash & Cash equivalents at the beginning of the year | 133,918 | 102,304 | ||||||
| Exchange rate differences on cash & cash equivalents | 684 | (915 | ) | |||||
| Cash & cash equivalents at end of the period | 153,529 | 132,052 | ||||||
Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)
| for the three months ended September 30, | for the nine months ended September 30, | |||||||||||||||
| In 000€ | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net profit (loss) for the period | 1,383 | 1,848 | 6,535 | 1,510 | ||||||||||||
| Income taxes | 120 | 553 | 478 | 266 | ||||||||||||
| Financial expenses | 1,128 | 582 | 2,699 | 7,393 | ||||||||||||
| Financial income | (1,289 | ) | (460 | ) | (3,494 | ) | (3,345 | ) | ||||||||
| Depreciation and amortization | 5,561 | 5,509 | 16,852 | 16,240 | ||||||||||||
| EBITDA | 6,904 | 8,031 | 23,070 | 22,065 | ||||||||||||
| Share-based compensation expense (1) | 360 | 74 | 475 | 191 | ||||||||||||
| Restructuring and corporate initiatives (2) | 577 | 322 | 1,012 | 605 | ||||||||||||
| Impairments (3) | 184 | - | 940 | - | ||||||||||||
| Divestitures-related expenses (4) | 22 | - | 191 | - | ||||||||||||
| Adjusted EBITDA | 8,046 | 8,428 | 25,688 | 22,862 | ||||||||||||
(1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.
(2) Non-recurring costs related to corporate initiatives, restructurings or reorganizations.
(3) Impairments represent the impairment of tangible and intangible assets and inventory of RapidFit NV and Eyewear resulting from the transfer of the assets to their respective management teams.
(4) Divestitures-related expenses represent fees and costs in connection with the divestitures of RapidFit and Eyewear.
Reconciliation of Net Profit (Loss) to EBIT and Adjusted EBIT (Unaudited)
| for the three months ended September 30, | for the nine months ended September 30, | |||||||||||||||
| In 000€ | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net profit (loss) for the period | 1,383 | 1,848 | 6,535 | 1,510 | ||||||||||||
| Income taxes | 120 | 553 | 478 | 266 | ||||||||||||
| Financial expenses | 1,128 | 582 | 2,699 | 7,393 | ||||||||||||
| Financial income | (1,289 | ) | (460 | ) | (3,494 | ) | (3,345 | ) | ||||||||
| EBIT | 1,343 | 2,522 | 6,218 | 5,825 | ||||||||||||
| Share-based compensation expense (1) | 360 | 74 | 475 | 191 | ||||||||||||
| Restructuring and corporate initiatives (2) | 577 | 322 | 1,012 | 605 | ||||||||||||
| Impairments (3) | 184 | - | 940 | - | ||||||||||||
| Divestitures-related expenses (4) | 22 | - | 191 | - | ||||||||||||
| Adjusted EBIT | 2,485 | 2,918 | 8,836 | 6,621 | ||||||||||||
(1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.
(2) Non-recurring costs related to corporate initiatives, restructurings or reorganizations.
(3) Impairments represent the impairment of tangible and intangible assets and inventory of RapidFit NV and Eyewear resulting from the transfer of the assets to their respective management teams.
(4) Divestitures-related expenses represent fees and costs in connection with the divestitures of RapidFit and Eyewear.
Segment P&L (Unaudited)
| In 000€ | Materialise Medical | Materialise Software | Materialise Manufacturing | Total segments | Unallocated (1) | Consolidated | ||||||||||||||||||
| For the three months ended September 30, 2026 | ||||||||||||||||||||||||
| Revenues | 36,542 | 9,864 | 21,266 | 67,672 | (2 | ) | 67,670 | |||||||||||||||||
| Segment (adj) EBITDA | 10,015 | 1,463 | (257 | ) | 11,220 | (3,174 | ) | 8,046 | ||||||||||||||||
| Segment (adj) EBITDA % | 27.4 | % | 14.8 | % | -1.2 | % | 16.6 | % | 11.9 | % | ||||||||||||||
| For the three months ended September 30, 2025 | ||||||||||||||||||||||||
| Revenues | 33,296 | 10,286 | 22,677 | 66,259 | 0 | 66,259 | ||||||||||||||||||
| Segment (adj) EBITDA | 10,199 | 1,801 | (845 | ) | 11,155 | (2,728 | ) | 8,428 | ||||||||||||||||
| Segment (adj) EBITDA % | 30.6 | % | 17.5 | % | -3.7 | % | 16.8 | % | 12.7 | % | ||||||||||||||
| In 000€ | Materialise Medical | Materialise Software | Materialise Manufacturing | Total segments | Unallocated (1) | Consolidated | ||||||||||||||||||
| For the nine months ended September 30, 2026 | ||||||||||||||||||||||||
| Revenues | 106,581 | 29,106 | 68,333 | 204,020 | 0 | 204,020 | ||||||||||||||||||
| Segment (adj) EBITDA | 30,802 | 3,566 | (262 | ) | 34,106 | (8,419 | ) | 25,688 | ||||||||||||||||
| Segment (adj) EBITDA % | 28.9 | % | 12.3 | % | -0.4 | % | 16.7 | % | 12.6 | % | ||||||||||||||
| For the nine months ended September 30, 2025 | ||||||||||||||||||||||||
| Revenues | 97,224 | 29,933 | 70,313 | 197,469 | 0 | 197,469 | ||||||||||||||||||
| Segment (adj) EBITDA | 29,974 | 3,772 | (2,031 | ) | 31,716 | (8,854 | ) | 22,862 | ||||||||||||||||
| Segment (adj) EBITDA % | 30.8 | % | 12.6 | % | -2.9 | % | 16.1 | % | 11.6 | % | ||||||||||||||
(1) Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition expenses related to business combinations or divestiture-related expenses, impairments and revaluation of fair value of business combinations and non-recurring costs related to corporate initiatives, restructurings and reorganizations that are included in Adjusted EBITDA and that are not allocated to the reporting segments .
Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited)
| for the three months ended September 30, | for the nine months ended September 30, | |||||||||||||||
| In 000€ | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net profit (loss) for the period | 1,383 | 1,848 | 6,535 | 1,510 | ||||||||||||
| Income taxes | 120 | 553 | 478 | 266 | ||||||||||||
| Financial expenses | 1,128 | 582 | 2,699 | 7,393 | ||||||||||||
| Financial income | (1,289 | ) | (460 | ) | (3,494 | ) | (3,345 | ) | ||||||||
| Operating (loss) profit | 1,343 | 2,522 | 6,218 | 5,825 | ||||||||||||
| Depreciation and amortization | 5,561 | 5,509 | 16,852 | 16,240 | ||||||||||||
| Corporate research and development | 1,127 | 826 | 2,941 | 2,926 | ||||||||||||
| Corporate headquarter costs | 3,753 | 2,761 | 9,969 | 8,512 | ||||||||||||
| Other operating income (expense) | (966 | ) | (685 | ) | (3,091 | ) | (2,187 | ) | ||||||||
| Impairments (1) | 184 | - | 940 | - | ||||||||||||
| Segment restructuring and reorganization (2) | 219 | 222 | 278 | 400 | ||||||||||||
| Segment adjusted EBITDA | 11,220 | 11,155 | 34,106 | 31,716 | ||||||||||||
(1) Impairments represent the impairment of tangible and intangible assets and inventory of RapidFit NV and Eyewear resulting from the transfer of the assets to their respective management teams.
(2) Costs related to restructuring activities and organizational changes within specific reported business segments, including personnel-related and other associated expenses.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MATERIALISE NV | ||
| By: |
/s/ Brigitte de Vet-Veithen |
|
| Name: | Brigitte de Vet-Veithen | |
| De Vet Management BV | ||
| Title: | Chief Executive Officer | |
Date: October 29, 2026